MLI Certified

On-Demand Activities

More results...

Therapeutics Areas

Learner Specialties

Expires After

On-Demand

Episode 2 of 3: Overcoming Barriers to Prescribing: A Med Table Talk™: Targeted Therapy in Atopic Dermatitis Series

Credit: .75hr(s)
CME

April 29, 2022 —
September 1, 2023

Therapeutic Areas: Allergy, Dermatology
Specialties: Atopic Dermatitis
Location: Internet Enduring Activity

View Course Description

In episode 2 of the 3-part educational initiative TRANSFORMING TARGETED THERAPY IN ATOPIC DERMATITIS: APPLYING EMERGING DATA AND EVOLVING BEST PRACTICES TO IMPROVE OUTCOMES, dermatologists and allergists discuss overcoming barriers to the use of oral JAK inhibitors. This activity focuses on the mechanistic rationale for the benefit and risk profiles of oral JAK inhibitors, how to address the black box warnings, and making treatment decisions based on patients’ values and goals.

On-Demand

Improving Survival in First-Line Metastatic NSCLC with Dual Checkpoint Blockade: Real-world Applications in Clinical Practice / Activity 2

Credit: 0.50hr(s)
AAPA, CME, CPE, NCPD

February 17, 2023 —
February 16, 2024

Therapeutic Areas: Hematologic Oncology, Oncology
Specialties: NSCLC, Oncology
Location: Internet Activity Enduring

View Course Description

This educational initiative is designed for community-based oncology clinicians (physicians, nurse practitioners [NPs], physician assistants [PAs], pharmacists, and nurses) to enhance outcomes for individuals with who provide care for individuals with mNSCLC. This interactive online activity uses the game-based platform Kahoot! to test participant ability to identify and apply key learning points to metastatic NSCLC (mNSCLC) patient cases while competing against their colleagues. Expert faculty will discuss the emerging efficacy and safety data for CTLA-4 inhibitor combination regimens in mNSCLC and explore strategies to identify patients who would most benefit from these therapies through the use of biomarkers. Additionally, there will be an in-depth discussion regarding approaches to effectively collaborate with other clinicians and mNSCLC patients to provide cost-effective, equitable, and inclusive care for patients of all socioeconomic and racial/ethnic backgrounds. Join us for Part 1 of this question and answer based educational activity, Improving Survival in First-line Metastatic NSCLC with Dual Checkpoint Blockade: Exploring Recent Data and Treatment Strategies for an in-depth dive into the data!

On-Demand

New Horizons in Multiple Myeloma Treatment: The Promise of CAR-T for Early Relapsed Disease

Credit: 1.00hr(s)
AAPA, CME, CPE, IPCE, NCPD

May 31, 2023 —
May 30, 2024

Therapeutic Areas: Hematologic Oncology, Hematology, Oncology
Specialties: CAR T-Cell Therapy, Multiple Myeloma
Location: Internet Activity Enduring

View Course Description

Despite remarkable progress, significant gaps remain in meeting the needs of patients facing relapse in multiple myeloma, particularly among patients with early relapse or triple-class exposed disease. Join us for a groundbreaking Special Edition Med Table Talk episode where we delve into the latest advancements in the treatment of relapsed multiple myeloma (RRMM). This candid conversation between esteemed faculty experts discusses the latest clinical evidence and rationale for CAR T-cell therapy in early versus late relapse settings and embraces a future pathway where highly effective treatments may be delivered earlier to support increasingly durable responses for complex patient populations.

On-Demand

Expanding Therapy Options for the Treatment of Relapsed or Refractory Multiple Myeloma: BCMA-Directed Therapies

Credit: 2.00hr(s)
CME, EBAH, ECMEC

April 13, 2023 —
February 8, 2024

Therapeutic Areas: Hematology, Oncology
Specialties: Multiple Myeloma
Location: Internet Activity Enduring

View Course Description

Join us in this 3-part educational Med Table Talk® on Expanding Therapy Options for the Treatment of Relapsed or Refractory Multiple Myeloma (RRMM): BCMA-Directed Therapies as our experts from the US and Western Europe have a candid conversation about the role of BCMA in MM, the clinical implications of new and emerging BCMA-directed therapies, and practical strategies for treatment sequencing.

On-Demand

Episode 1 of 3: What You Need to Know About New Targeted Therapies for AD

Credit: 0.75hr(s)
CME

April 22, 2022 —
September 1, 2023

Therapeutic Areas: Allergy, Dermatology
Specialties: Atopic Dermatitis
Location: Internet Enduring Activity

View Course Description

In episode 1 of the 3-part educational initiative TRANSFORMING TARGETED THERAPY IN ATOPIC DERMATITIS: APPLYING EMERGING DATA AND EVOLVING BEST PRACTICES TO IMPROVE OUTCOMES, dermatologists and allergists discuss what practicing clinicians need to know about newly approved oral JAK inhibitors. This activity focuses on the mechanism of action of novel targeted agents, their key safety and efficacy data, and their role in the treatment paradigm for atopic dermatitis.

On-Demand

Making the Right Call: Biomarker Testing and Targeting in NSCLC: Part I: Equitable, Guideline-based Testing for Prognosis and Treatment

Credit: 0.30hr(s)
AAPA, CME, CPE, NCPD

November 29, 2022 —
November 28, 2023

Therapeutic Areas: Hematologic Oncology, Hematology, Oncology
Specialties: Biomarkers, NSCLC
Location: Internet Activity Enduring

View Course Description

In the past decade, advances in non-small cell lung cancer (NSCLC) have rapidly evolved with the discovery of targetable mutations and subsequent therapies. However, suboptimal biomarker testing practices and varying adherence to testing guidelines presents a challenge to implementing targeted treatment. Are you ready to test your skills against those of your colleagues? Join us for Part 1 of this question and answer based educational activity Equitable, Guideline-based Testing for Prognosis and Treatment where our oncology experts will: Review guideline recommendations for biomarker testing and treatment selection Present clinical evidence for the use of current and emerging targeted therapies Discuss health disparities in biomarker testing

On-Demand

Build Your Own Case Study | Obesity: Treating the Whole Patient

Credit: 1.0hr(s)
AAPA, CME, CPE, NCPD

April 27, 2023 —
April 26, 2024

Therapeutic Areas: Endocrinology, Family Medicine / Primary Care
Specialties: Obesity
Location: Internet Activity Enduring

View Course Description

Obesity is a chronic, progressive, relapsing disease that impacts health and quality of life. In individuals with obesity, there are many contributors to its development and persistence, including lifestyle, social, and economic factors. If left untreated, obesity can be a primary driver of serious health consequences. By treating obesity first, complications arising from obesity may improve or resolve. Given the severity of the disease, there is a need for clinicians in primary and specialty care settings to diagnose and treat obesity so that patients can receive the most appropriate treatment and care. Evidence-based treatment options, including anti-obesity medications, are emerging for adults and children. In this immersive virtual Build Your Own Case Study | Obesity: Treating the Whole Patient, navigate through your toughest clinical challenges while leading experts reinforce essential topics, such as: Medical consequences and comorbidities of obesity Application of adiposity measures, including BMI and waist circumference Latest clinical evidence of new and emerging anti-obesity medications Best practices in shared decision-making and starting the conversation with your patients

On-Demand

GVHD 5 - ECHO Program: Atypical Manifestations of Chronic GVHD

Credit: 1.0hr(s)

December 8, 2022 —
December 8, 2023

Therapeutic Areas: Dermatology, Family Medicine / Primary Care, Internal Medicine, Rheumatology
Specialties: Primary Care
Location: Internet Activity Enduring

View Course Description

The goal of the GVHD Interactive Provider Network ECHO Program is to connect GVHD specialists with community providers to share expertise, discuss cases and improve patient care. The network is based on the ECHO Model™ (Extension for Community Healthcare Outcomes) which uses proven adult learning techniques and interactive video technology to connect community providers with specialists in collaborative sessions. The sessions, designed around case-based learning and mentorship, will help primary care and community-based practitioners gain the practical expertise required to care for GVHD patients. Questions and comments from the learners will be encouraged to facilitate discussion.

On-Demand

The Evolution of HCT, Part 1: Basics and Outcomes

Credit: 1.50hr(s)
CME, NCPD

February 22, 2023 —
February 21, 2024

Therapeutic Areas: Hematologic Oncology, Hematology, Hematopoietic Cell Transplantation (HCT), Oncology
Specialties: Bone Marrow Transplantation, Hematology, Oncology
Location: Internet Activity Enduring

View Course Description

Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 1 in a 5-part series, including the series introduction, basics of HCT, and major advances in HCT outcomes over time.

On-Demand

Potential Benefits of Incretins Beyond Glycemic Control in T2D

Credit: 1.0hr(s)
CME

October 14, 2022 —
October 29, 2023

Therapeutic Areas: Diabetes, Endocrinology
Specialties: Diabetes, Endocrinology
Location: Internet Activity Enduring

View Course Description

Despite the growing list of safe and effective therapies for individuals with T2D, many patients struggle to achieve their glucose target and thus remain at risk for significant comorbidities. Novel unimolecular dual agonists may help address these unmet needs. What role might novel agents play, and how can endocrinologists engage with their patients to make better therapeutic choices? During the session, experts will explain the incretin effect and the roles of GLP-1 and GIP, as well as the potential benefits of agonism of multiple receptors that affect energy homeostasis; they will also interpret the clinical implications of new and emerging data for the first-in-class dual GLP-1 and GIP agonist. Case studies will identify individuals with T2D who may benefit from earlier treatment intensification to improve overall health and delineate practical considerations to help individuals with T2D achieve optimal outcomes. This taped satellite symposium was derived from the 58th EASD Annual Meeting on September 19, 2022.

On-Demand

Advancing the Standard of Care for Relapsed/Refractory Multiple Myeloma: BCMA-directed Therapy

Credit: 0.50hr(s)
AAPA, CME, CPE, NCPD

January 26, 2023 —
February 8, 2024

Therapeutic Areas: Hematologic Oncology, Oncology
Specialties: Multiple Myeloma
Location: Internet Activity Enduring

View Course Description

B-cell maturation antigen (BCMA) plays a promising role as a therapeutic target. In fact, several BCMA-directed therapy modalities, including bispecific antibodies, chimeric-antigen receptor T-cell (CART), and antibody-drug conjugates, are available or in development for patients with relapsed/refractory multiple myeloma (RRMM). Even with the advances in the treatment regime, it is important for oncology teams to understand the implications of the clinical data. Tune into the 1st episode of the Med Table Talk® Advancing the Standard of Care for Relapsed/Refractory Multiple Myeloma: BCMA-directed Therapy, where our leading experts will discuss: The rationale, mechanism of action, and efficacy and safety of currently available BCMA-directed therapies Prevention and management strategies for adverse events associated with BCMA agents The unmet need for representation in clinical trials

On-Demand

Episode 2 of 4 - Biomarker Testing: Shaping Personalized Medicine

Credit: 0.15hr(s)
NCPD

November 22, 2022 —
November 28, 2023

Therapeutic Areas: Hematologic Oncology, Oncology
Specialties: Biomarkers, NSCLC
Location: Internet Activity Enduring

View Course Description

For non-small cell lung cancer (NSCLC), the rates of 5-year survival have improved significantly over the past 10 years with improved early detection methods and the approval of highly effective targeted therapies. With an expansion of the treatment arsenal, it is up to clinicians to decipher the latest guideline recommendations and apply evolving clinical evidence to ensure optimal treatment selection and patient education. Join us for the second episode of the 4-part educational initiative Biomarker-based Therapy for NSCLC: Improving Collaboration, Communication, and Care in which our expert faculty explore the implications of test results for prognosis and discuss methods to empower patients to engage in their care.

On-Demand

Episode 1 of 3 - What You MUST Know About the Emerging Standard of Care for 1L Treatment of CLL and SLL

Credit: 0.30hr(s)
AAPA, CME, CPE, NCPD

December 1, 2023 —
December 14, 2023

Therapeutic Areas: Hematologic Oncology, Oncology
Specialties: Chronic Lymphocytic Leukemia (CLL), Small lymphocytic lymphoma (SLL)
Location: Internet Activity Enduring

View Course Description

The treatment landscape in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has shifted with the advent of novel targeted agents that are more tolerable than traditional chemoimmunotherapy. However, keeping up with the latest clinical evidence and updates to the clinical guidelines on these agents can be challenging for busy clinicians and their care teams. In this first episode of the 3-part educational series First-line Treatment of CLL/SLL: New Data and Practical Strategies for Practice Improvement, sit in on a conversation with our expert faculty as they discuss the new standard of care for CLL and SLL and how to apply this care transition to your patients and clinic.

On-Demand

The Evolution of HCT, Part 3: Donor Availability

Credit: 0.75hr(s)
CME, NCPD

February 22, 2023 —
February 21, 2024

Therapeutic Areas: Hematologic Oncology, Hematology, Hematopoietic Cell Transplantation (HCT), Oncology
Specialties: Bone Marrow Transplantation, Hematology, Oncology
Location: Internet Activity Enduring

View Course Description

Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 3 in a 5-part series, covering advances in donor availability that have led to expanded access to HCT over time.

On-Demand

Episode 3 of 4 - Novel Therapeutics: Changing the Treatment Landscape for NSCLC

Credit: 0.15hr(s)
NCPD

November 28, 2022 —
November 28, 2023

Therapeutic Areas: Hematologic Oncology, Oncology
Specialties: Biomarkers, NSCLC
Location: Internet Activity Enduring

View Course Description

Targeted therapies have revolutionized the treatment of non-small cell lung cancer (NSCLC) with actionable genetic alterations. However, the constantly changing treatment landscape plus the rapidly evolving clinical evidence and guidelines present challenges for busy oncology nursing teams. Tune into the third episode of the 4-part educational initiative Biomarker-based Therapy for NSCLC: Improving Collaboration, Communication, and Care to learn from about new and emerging targeted therapies for NSCLC and best practices for managing patients with acquired resistance.

Clinical Pearl

GVHD-E4 | ECHO Program: Bronchiolitis Obliterans

Credit: 1.0hr(s)
CME, NCPD

November 2, 2022 —
November 2, 2023

Therapeutic Areas: Family Medicine / Primary Care, General Medicine
Specialties: Primary Care
Location: Internet Activity Enduring

View Course Description

The goal of the GVHD Interactive Provider Network ECHO Program is to connect GVHD specialists with community providers to share expertise, discuss cases and improve patient care. The network is based on the ECHO Model™ (Extension for Community Healthcare Outcomes) which uses proven adult learning techniques and interactive video technology to connect community providers with specialists in collaborative sessions. The sessions, designed around case-based learning and mentorship, will help primary care and community-based practitioners gain the practical expertise required to care for GVHD patients.

On-Demand

The Evolution of HCT, Part 5: Shared Care

Credit: 0.75hr(s)
CME, NCPD

February 22, 2023 —
February 21, 2024

Therapeutic Areas: Hematologic Oncology, Hematology, Hematopoietic Cell Transplantation (HCT), Oncology
Specialties: Bone Marrow Transplantation, Hematology, Oncology
Location: Internet Activity Enduring

View Course Description

Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 5 in a 5-part series, exploring how shared and coordinated care between transplant centers and hematology/oncology practices can help overcome barriers to HCT and improve patient outcomes and experience.

On-Demand

Mastering MRD for Prognosis and Treatment in ALL

Credit: 1.0hr(s)
CME, CPE, MOC, NCPD

October 14, 2022 —
October 29, 2023

Therapeutic Areas: Hematologic Oncology, Hematology, Oncology, Pathology
Specialties: Acute Lymphocytic Leukemia (ALL), Leukemia, Minimal Residual Disease
Location: Internet Activity Enduring

View Course Description

Acute lymphoblastic leukemia (ALL) is the first hematologic neoplasm for which assessment of early response to therapy using measurable residual disease (MRD) has proven to be a fundamental tool for guiding therapy. It should be a key component in individualizing care to improve outcomes for patients. But MRD is a time point-dependent variable, with different time points signifying different prognosis for relapse. And MRD testing methods are variable across clinical practices, and it can be challenging to select the appropriate combination and sequence of therapy. Consequently, not all patients are provided with uniform care. During Mastering MRD for Prognosis and Treatment in ALL, experts will discuss conducting MRD testing for patients with ALL according to the guideline-recommended schedule; evaluating the specimens needed for, and the pros and cons of, various methods for assessing MRD; predicting the risk of relapse based on MRD test results; and individualizing treatment based on MRD status to ensure patients at higher risk of relapse receive appropriate risk-adapted therapy. This taped Satellite Symposium was derived from the Society of Hematologic Oncology 2022 Annual Meeting.

On-Demand

Transitioning from Chemoimmunotherapy to More Targeted Approaches in MCL

Credit: 1.0hr(s)
CME, CPE, MOC, NCPD

October 14, 2022 —
October 30, 2023

Therapeutic Areas: Hematologic Oncology, Hematology, Oncology, Pathology
Specialties: Lymphoma, Mantle Cell Lymphoma
Location: Internet Activity Enduring

View Course Description

The natural history of mantle cell lymphoma (MCL) is a repeated pattern of remission and relapse; after a few relapses, patients have a very small chance of responding to any therapy. Considerable progress has been made over the last decade as the treatment paradigm has shifted from traditional chemoimmunotherapy toward targeted and cell-based therapies in both the frontline and relapsed/refractory (R/R) settings. However, selecting the best treatment is often complicated, involving multiple patient factors, and there is no established standard of care. During Transitioning from Chemoimmunotherapy to More Targeted Approaches in MCL, experts discuss using prognostic tools to plan treatment for individuals with MCL and targetable mutations, integrating emerging data and guidelines recommendations for front-line treatment, potential benefits and risks of chemotherapy-free targeted options, planning safe and effective use of novel therapies and combinations in the second- and third-line settings and for R/R MCL, and eradicating health inequities and closing the survival gap. This taped Satellite Symposium was derived from the Society of Hematologic Oncology 2022 Annual Meeting.

On-Demand

Build Your Own Case Study: A Glimpse at Optimal T2D Management: Enhancing Outcomes with GLP-1 RAs

Credit: 1.0hr(s)
CME, CPE, NCPD, Physician Assistants

October 28, 2023 —
October 27, 2023

Therapeutic Areas: Diabetes, Endocrinology
Specialties: Diabetes, Endocrinology
Location: Internet Activity Enduring

View Course Description

Think you fully understand the differences between available glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and their use in the management of Type 2 diabetes (T2D) and comorbidities? Clinicians may under-use GLP-1 RAs or not fully understand the differences between all the available GLP-1 RAs. As a result, unmet needs in T2D management persist, particularly in some ethnic and socioeconomic populations. Test your knowledge about newest guideline recommendations, current evidence, and strategies to individualize treatment for patients with T2D using GLP-1 RAs by building your own case studies. This will help your patients achieve A1C targets, particularly those with comorbidities including obesity, cardiovascular disease, NAFLD/NASH, transplants, PCOS and more! Additionally, this will help you identify various social determinants of health (SDoH) that may be unrecognizable and help you direct your patients in changing important modifiable behaviors (like sleep, stress, smoking cessation, and alcohol use). At any point in this Build Your Own Case Study, expert endocrinologists will shed light on current recommendations and evidence for GLP-1 RAs in the management of T2D along with obesity, cardiovascular diseases, and other comorbidities. Our expert faculty will also offer insights on individualizing treatment plans to help your patients reach their goals and reduce comorbidity risks. Think you have all the tools you need to help your patients? If so, post-test and claiming credit will be a breeze!

On-Demand

Episode 1 of 2: Talk to Me About Dual Agonists

Credit: 0.5hr(s)
CME, Dietitian, NCPD, Pharmacists, Physician Assistants

September 12, 2022 —
September 11, 2023

Therapeutic Areas: Diabetes, Endocrinology
Specialties: Diabetes, Endocrinology
Location: Internet Activity Enduring

View Course Description

For prescribers and non-prescribers alike, therapeutic inertia can be a big challenge when trying to optimize therapy to control patients’ glucose levels and improve their overall health. Such obstacles can be even more difficult when trying to switch treatment regimens. Novel therapies can be miracles, but only if patients can actually get them. In Talk to Me About Dual Agonists, episode 1 of the Med Table TalkTM series, certified diabetes care and education specialists address therapeutic inertia and the need to treat the whole person, rather than just A1C. They then explain the mechanisms of action, efficacy and safety, and precautions for using a unimolecular dual agonist and strategies for helping patients gain access.

On-Demand

The Evolution of HCT, Part 2: Eligibility

Credit: 0.75hr(s)
CME, NCPD

February 22, 2023 —
February 21, 2024

Therapeutic Areas: Hematologic Oncology, Hematology, Hematopoietic Cell Transplantation (HCT), Oncology
Specialties: Bone Marrow Transplantation, Hematology, Oncology
Location: Internet Activity Enduring

View Course Description

Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 2 in a 5-part series, covering advances that have expanded eligibility for HCT and considerations for who is a candidate.

On-Demand

Personalizing Treatment Options Across the Continuum of MDS and sAML

Credit: 1.0hr(s)
CME, CPE, NCPD

September 28, 2022 —
September 27, 2023

Therapeutic Areas: Hematologic Oncology, Hematology, Oncology
Specialties: MDS, Secondary AML
Location: Internet Activity Enduring

View Course Description

The number of approved drugs for myelodysplastic syndromes (MDS) is limited, and not all agents have been shown to be highly efficacious and to improve survival. However, the oncology community witnessed an explosion of new agents and investigational approaches in 2020 that has persisted until today. In this virtual symposium hear expert insights regarding the role of cytogenetic abnormalities, new prognostic models, and other patient- and disease-related factors in diagnosis, prognosis, and treatment planning for individuals with MDS. Faculty will also assess the clinical implications of recent and emerging safety and efficacy data for novel agents and combinations and provide strategies for effective communication with patients, including those in special populations and those of diverse backgrounds, to manage symptoms and enhance quality of life. This virtual Satellite Symposium was derived from the Society of Hematologic Oncology 2022 Annual Meeting.

On-Demand

GVHD-E1 | ECHO Program: Treatment Decisions in Chronic GVHD

Credit: 1.0hr(s)
CME, NCPD

September 16, 2022 —
September 16, 2023

Therapeutic Areas: Family Medicine / Primary Care, General Medicine
Specialties: Primary Care
Location: Internet Activity Enduring

View Course Description

The goal of the GVHD Interactive Provider Network ECHO Program is to connect GVHD specialists with community providers to share expertise, discuss cases and improve patient care. The network is based on the ECHO Model™ (Extension for Community Healthcare Outcomes) which uses proven adult learning techniques and interactive video technology to connect community providers with specialists in collaborative sessions. The sessions, designed around case-based learning and mentorship, will help primary care and community-based practitioners gain the practical expertise required to care for GVHD patients.